3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Conditions
Mucositis
4
Hematologic Neoplasms
3
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Thrombocytopenia
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neutropenia
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphopenia
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Graft vs Host Disease
1
Cytopenia
1
Anemia
1
Interventions
Brentuximab Vedotin
27
pembrolizumab
13
Nivolumab
11
Dacarbazine
8
Vinblastine
7
Doxorubicin
7
Gemcitabine
6
Bendamustine Hydrochloride
6
plerixafor
5
fludarabine
4
Rituximab
4
Granulocyte Colony-Stimulating Factor
4
Cyclophosphamide
4
Azacitidine
4
abexinostat
3
Melphalan
3
Filgrastim
3
Etoposide
3
Busulfan
3
Bleomycin
3
umbralisib
2
relatlimab
2
pegfilgrastim
2
mocetinostat
2
itacitinib
2
givinostat hydrochloride
2
givinostat
2
fludarabine phosphate
2
durvalumab
2
cc-486
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hodgkin Disease
×
angiotensin I (1-7)
×
Clear all
NCT01121120
2020-12-08
TXA127-PBSC
Tarix Pharmaceuticals
Phase 2
Terminated
75 enrolled
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled